Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.92 HKD -2.97% Market Closed
Market Cap: 2.7B HKD

Antengene Corporation Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Antengene Corporation Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
Net Income (Common)
-ÂĄ319.3m
CAGR 3-Years
21%
CAGR 5-Years
0%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
ÂĄ4.8B
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
ÂĄ2.4B
CAGR 3-Years
-1%
CAGR 5-Years
9%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
ÂĄ7.5B
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
ÂĄ5.2B
CAGR 3-Years
25%
CAGR 5-Years
1%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
ÂĄ3.7B
CAGR 3-Years
N/A
CAGR 5-Years
244%
CAGR 10-Years
N/A
No Stocks Found

Antengene Corporation Ltd
Glance View

Market Cap
2.7B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.86 HKD
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Antengene Corporation Ltd's Net Income (Common)?
Net Income (Common)
-319.3m CNY

Based on the financial report for Dec 31, 2024, Antengene Corporation Ltd's Net Income (Common) amounts to -319.3m CNY.

What is Antengene Corporation Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
0%

Over the last year, the Net Income (Common) growth was 45%. The average annual Net Income (Common) growth rates for Antengene Corporation Ltd have been 21% over the past three years .

Back to Top